Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine

Vaccine

Volumn 31, Issue 35, 2013, Pages 3603-3610

  Frasca, Daniela ^a   Diaz, Alain ^a,b,c   Romero, Maria ^a   Mendez, Nicholas V ^a   Landin, Ana Marie ^a   Ryan, John G ^a   Blomberg, Bonnie B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b School of Advanced Studies   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Antibody responses; Inflammation; Influenza vaccine; Type 2 diabetes

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ADIPONECTIN; C REACTIVE PROTEIN; CD14 ANTIGEN; INFLUENZA VACCINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; GROUPS BY AGE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLUENZA VACCINATION; LYMPHOCYTE FUNCTION; MALE; MEMORY CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEASONAL INFLUENZA; TREATMENT RESPONSE;

ANTIBODY RESPONSES; INFLAMMATION; INFLUENZA VACCINE; TYPE 2 DIABETES;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CYTIDINE DEAMINASE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOLOGIC MEMORY; INFLAMMATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84880709954     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.003     Document Type: Article

References (45)

1. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
2. Nikolajczyk B.S. B cells as under-appreciated mediators of non-auto-immune inflammatory disease. Cytokine 2010, 50:234-242.
3. Apovian C.M., Bigornia S., Mott M., Meyers M.R., Ulloor J., Gagua M., et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008, 28:1654-1659.
4. Strissel K.J., Stancheva Z., Miyoshi H., Perfield J.W., DeFuria J., Jick Z., et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007, 56:2910-2918.
5. Senn J.J. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 2006, 281:26865-26875.
6. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025.
7. Bowie A., O'Neill L.A. The interleukin-1 receptor/toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 2000, 67:508-514.
8. Nikolajczyk B.S., Jagannathan-Bogdan M., Shin H., Gyurko R. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun 2011, 12:239-250.
9. Duffaut C., Galitzky J., Lafontan M., Bouloumie A. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem Biophys Res Commun 2009, 384:482-485.
10. Muller L.M., Gorter K.J., Hak E., Goudzwaard W.L., Schellevis F.G., Hoepelman A.I., et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005, 41:281-288.
11. Pozzilli P., Gale E.A., Visalli N., Baroni M., Crovari P., Frighi V., et al. The immune response to influenza vaccination in diabetic patients. Diabetologia 1986, 29:850-854.
12. Smith S.A., Poland G.A. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 2000, 23:95-108.
13. Eickhoff T.C., Sherman I.L., Serfling R.E. Observations on excess mortality associated with epidemic influenza. JAMA 1961, 176:776-782.
14. el-Madhun A.S., Cox R.J., Seime A., Sovik O., Haaheim L.R. Systemic and local immune responses after parenteral influenza vaccination in juvenile diabetic patients and healthy controls: results from a pilot study. Vaccine 1998, 16:156-160.
15. Brydak L.B., Machala M. Humoral immune response to influenza vaccination in patients from high risk groups. Drugs 2000, 60:35-53.
16. Marti A., Marcos A., Martinez J.A. Obesity and immune function relationships. Obes Rev 2001, 2:131-140.
17. Colquhoun A.J., Nicholson K.G., Botha J.L., Raymond N.T. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 1997, 119:335-341.
18. Hak E., Nordin J., Wei F., Mullooly J., Poblete S., Strikas R., et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002, 35:370-377.
19. Heymann A.D., Shapiro Y., Chodick G., Shalev V., Kokia E., Kramer E., et al. Reduced hospitalizations and death associated with influenza vaccination among patients with and without diabetes. Diabetes Care 2004, 27:2581-2584.
20. Looijmans-Van den Akker I., Verheij T.J., Buskens E., Nichol K.L., Rutten G.E., Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care 2006, 29:1771-1776.
21. McElhaney J.E., Pinkoski M.J., Au D., Lechelt K.E., Bleackley R.C., Meneilly G.S. Helper and cytotoxic T lymphocyte responses to influenza vaccination in healthy compared to diabetic elderly. Vaccine 1996, 14:539-544.
22. Ferrucci L., Corsi A., Lauretani F., Bandinelli S., Bartali B., Taub D.D., et al. The origins of age-related proinflammatory state. Blood 2005, 105:2294-2299.
23. Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured?. Nutr Rev 2007, 65:S173-S176.
24. Franceschi C., Capri M., Monti D., Giunta S., Olivieri F., Sevini F., et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007, 128:92-105.
25. Frasca D., Romero M., Diaz A., Alter-Wolf S., Ratliff M., Landin A.M., et al. A molecular mechanism for TNF-alpha-mediated downregulation of B cell responses. J Immunol 2012, 188:279-286.
26. Frasca D., Diaz A., Romero M., Landin A.M., Phillips M., Lechner S.C., et al. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine 2010, 28:8077-8084.
27. Frasca D., Diaz A., Romero M., Phillips M., Mendez N.V., Landin A.M., et al. Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. Int Immunol 2012, 24:175-182.
28. Murasko D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002, 37:427-439.
29. Skowronski D.M., Tweed S.A., De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?. J Infect Dis 2008, 197:490-502.
30. Frasca D., Diaz A., Romero M., Landin A.M., Blomberg B.B. Age effects on B cells and humoral immunity in humans. Ageing Res Rev 2011, 10:330-335.
31. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
32. Frasca D., Landin A.M., Lechner S.C., Ryan J.G., Schwartz R., Riley R.L., et al. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J Immunol 2008, 180:5283-5290.
33. Fidan E., Onder Ersoz H., Yilmaz M., Yilmaz H., Kocak M., Karahan C., et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol 2011, 48:297-302.
34. Huang N.L., Chiang S.H., Hsueh C.H., Liang Y.J., Chen Y.J., Lai L.P. Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation. IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol 2009, 134:169-175.
35. Bailey C.J., Turner R.C., Metformin N. Engl J Med 1996, 334:574-579.
36. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
37. Ferraris R.P., Casirola D.M., Vinnakota R.R. Dietary carbohydrate enhances intestinal sugar transport in diabetic mice. Diabetes 1993, 42:1579-1587.
38. Kitchens R.L., Thompson P.A. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005, 11:225-229.
39. Gil-Campos M., Canete R.R., Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004, 23:963-974.
40. Lara-Castro C., Fu Y., Chung B.H., Garvey W.T. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007, 18:263-270.
41. Neumeier M., Bauer S., Bruhl H., Eisinger K., Kopp A., Abke S., et al. Adiponectin stimulates release of CCL2, -3, -4 and -5 while the surface abundance of CCR2 and -5 is simultaneously reduced in primary human monocytes. Cytokine 2011, 56:573-580.
42. Khurana S., Frasca D., Blomberg B.B., Golding H. Activation-induced cytidine deaminase (AID) activity in human B cells strongly correlates with polyclonal antibody affinity maturation in vivo following pandemic 2009 H1N1 vaccination. PLoS Pathog 2012, [in press].
43. Frasca D., Landin A.M., Riley R.L., Blomberg B.B. Mechanisms for decreased function of B cells in aged mice and humans. J Immunol 2008, 180:2741-2746.
44. Lassenius M.I., Pietilainen K.H., Kaartinen K., Pussinen P.J., Syrjanen J., Forsblom C., et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011, 34:1809-1815.
45. Barbosa R.R., Silva S.P., Silva S.L., Tendeiro R., Melo A.C., Pedro E., et al. Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels. Clin Exp Immunol 2012, 169:263-272.